Antibody molecules which bind cd45

Abstract

The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

1 - 39 . (canceled) 
     
     
         40 . An antibody molecule comprising a binding domain specific to CD45 comprising a heavy chain variable domain (VH) comprising: a CDRH1 comprising SEQ ID NO: 15 or 16, and a CDRH2 comprising SEQ ID NO: 29 or 30, and a CDRH3 comprising SEQ ID NO: 34, 35, 36 or 37; and a light chain variable domain (VL) comprising: a CDRL1 comprising SEQ ID NO: 41, 42, 43, 44, a CDRL2 comprising SEQ ID NO: 48 and a CDRL3 comprising SEQ ID NO: 59, with the proviso that the antibody does not comprise a CDRH1 comprising SEQ ID NO: 15, a CDRH2 comprising SEQ ID NO: 29, a CDRH3 comprising SEQ ID NO: 34, a CDRL1 comprising SEQ ID NO: 41, a CDRL2 comprising SEQ ID NO: 48 and a CDRL3 comprising SEQ ID NO: 59. 
     
     
         41 . The antibody molecule according to  claim 40  wherein the VH and VL are humanised. 
     
     
         42 . The antibody molecule according to  claim 41 , comprising a VH comprising SEQ ID NO: 94, 95, 96 or 97 and a VL comprising SEQ ID NO: 92 or 93. 
     
     
         43 . The antibody molecule according to  claim 41 , wherein the variable domain of the light chain has at least 80% identity to SEQ ID NO: 92 or 93 and wherein the variable domain of the heavy chain has at least 80% identity to SEQ ID NO: 94, 95, 96 or 97. 
     
     
         44 . The antibody molecule according to  claim 40  wherein the antibody is a full length antibody. 
     
     
         45 . The antibody molecule according to  claim 40  wherein the antibody is a scFv, Fv, Fab or Fab′ fragment. 
     
     
         46 . The antibody molecule according to  claim 40 , wherein the molecule is a multispecific molecule. 
     
     
         47 . The antibody molecule according to  claim 46 , which is bispecific or trispecific. 
     
     
         48 . The antibody molecule according to  claim 40 , wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv) 2  diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V and DVD-Ig. 
     
     
         49 . The antibody molecule according to  claim 46  comprising one binding domain which is specific to CD45 and one binding domain which is specific to CD79. 
     
     
         50 . The antibody molecule according to  claim 49 , wherein the multispecific molecule comprises no more than one binding domain which is specific to CD45 and no more than one binding domain which is specific to CD79a or CD79b. 
     
     
         51 . The multispecific molecule according to  claim 49  wherein the binding domain which is specific to CD45 and the binding domain which is specific to CD79 are independently selected from a Fab, scFv, Fv, dsFv and dsscFv. 
     
     
         52 . The antibody molecule according to  claim 40 , which further comprises a binding domain specific to serum albumin. 
     
     
         53 . The antibody molecule according to  claim 52 , which further comprises a binding domain specific to human serum albumin. 
     
     
         54 . A composition comprising one or more antibody molecules as defined in  claim 40 . 
     
     
         55 . An isolated nucleotide sequence encoding an antibody molecule as defined in  claim 40 . 
     
     
         56 . A vector comprising a nucleotide sequence defined in  claim 55 . 
     
     
         57 . A method of treating a patient, comprising the administration of a therapeutically effective amount of an antibody molecule according to  claim 40  or a composition according to  claim 54 .